Clinical and pathological correlations in male breast cancer: Intratumoral aromatase expression via tissue microarray

Breast Cancer Research and Treatment

Volumn 105, Issue 2, 2007, Pages 169-175

  Dakin Haché, Kelly ^a   Gray, Samantha ^a   Barnes, Penny J ^a   Dewar, Ron ^b   Younis, Tallal ^a   Rayson, Daniel ^a  

^a QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

^b Surveillance and Epidemiology Unit   (Canada)

Author keywords

Aromatase; Male breast cancer; Pathologic correlates

Indexed keywords

AROMATASE; AROMATASE INHIBITOR; HORMONE RECEPTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER SURVIVAL; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; SCORING SYSTEM; TISSUE MICROARRAY; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; AROMATASE; BREAST NEOPLASMS, MALE; DISEASE PROGRESSION; HUMANS; IMMUNOENZYME TECHNIQUES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; PROGNOSIS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; SURVIVAL RATE; TISSUE ARRAY ANALYSIS;

EID: 34548406877     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-006-9448-9     Document Type: Article

References (29)

1. Giordano SH, Buzdar AU, Hortobagyi GN (2002) Breast cancer in men. Ann Intern Med 137:678-687
2. Giordano SH, Cohen DS, Buzdar AU et al (2004) Breast carcinoma in men: a population-based study. Cancer 103(2):51-7
3. Scott-Conner CE, Jochimsen PR, Menck HR et al (1999) An analysis of male and female breast cancer treatment and survival among demographically identical pairs of patients. Surgery 126:775-780
4. Willsher PC, Leach IH, Ellis IO et al (1997) A comparison outcome of male breast cancer with female breast cancer. Am J Surg 173:185-188
5. Hill TD, Khamis HJ, Tyczynski et al (2005) Comparison of male and female breast cancer incidence trends, tumor characteristics, and survival. Ann Epidemiol 15(10):773-780
6. Joshi MG, Lee AKC, Loda M et al (1996) Male breast carcinoma: an evaluation of prognostic factors contributing to a poorer outcome. Cancer 77:490-498
7. Goodman MT, Tung KH, Wilkens LR (2006) Comparative epidemiology of breast cancer among men and women in the US, 1996 to 2000. Cancer Causes Control 17(2):127-136
8. Rudlowski C, Schulten HJ, Golas MM et al (2006) Comparative genomic hybridization analysis on male breast cancer. Int J Cancer 118(10):2455-2460
9. Goss PE, Reid C, Pintilie M et al (1999) Male breast carcinoma: a review of 229 patients who presented to the Princess Margaret Hospital during 40 years:1955-1996. Cancer 85(3):629-639
10. Nahleh ZA (2006) Hormonal therapy for male breast cancer: a different approach for a different disease. Cancer Treat Rev 32(2):101-105
11. Cutuli B, Lacroze M, Dilhuydy JM et al (1995) Male breast cancer: results of the treatments and prognostic factors in 397 cases. Eur J Cancer 31A:1960-1964
12. Rayson D, Erlichman C, Suman VJ et al (1998) Molecular markers in male breast carcinoma. Cancer 83(9):1947-1955
13. Muir D, Kanthan R, Kanthan SC (2003) Male versus female breast cancers. A population-based comparative immunohistochemical analysis. Arch Pathol Lab Med 127(1):36-41
14. Riva C, Dainese E, Caprara G et al (2005) Immunohistochemical study of androgen receptors in breast carcinoma. Evidence of their frequent expression in lobular carcinoma. Virchows Arch 447(4):695-700
15. Kwiatkowska E, Tevesiak M, Filas V et al (2003) BRCA2 mutations and androgen receptor expression as independent predictors of outcome of male breast cancer patients. Clin Cancer Res 9(12):4452-4459
16. Rudlowski C, Friedrichs N, Faridi A et al (2004) Her-2/neu gene amplification and protein expression in primary male breast cancer. Breast Cancer Res Treat 84(3):215-223
17. Bloom KJ, Govil H, Gattuso P et al (2001) Status of Her-2 in male and female breast carcinomas. Am J Surg 82:389-392
18. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy on recurrence and 15-year survival: an overview of the randomized trials. Lancet 365(9472):1687-1717
19. Berry DA, Cronin KA, Plevritis SK et al (2005) Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353:1784-1792
20. Coombes RC, Hall E, Gibson LJ et al (2004) A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350(11):1081-1092
21. Goss PE, Ingle JN, Martino S et al (2005) Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97:1262-1271
22. Zabolotny BP, Zalai CV, Meterissian SH (2005) Successful use of letrozole in male breast cancer: a case report and review of hormonal therapy for male breast cancer. J Surg Oncol 90(1):26-30
23. Sasano H, Kimura M, Shizawa N et al (1996) Aromatase and steroid receptors in gynecomastia and male breast cancer: an immunohistochemical study. J Clin Endocrinol Metab 81(8):3063-3067
24. Santner SJ, Pauley RJ, Tait L et al (1997) Aromatase activity and expression in breast cancer and benign breast tissue stromal cells. J Clin Endocrinol Metab 82:200-208
25. Lu Q, Nakamura J, Savinov A et al (1996) Expression of aromatase protein and messenger ribonucleic acid in tumour epithelial cells and evidence of functional significance of locally produced estrogen in human breast cancers. Endocrinology 137:3061-3068
26. Sasano H, Suzuki T, Nakata T et al (2006) New development in intracrinology of breast carcinoma. Breast Cancer 18(2):129-136
27. Camp RL, Charette LA, Rimm DL (2000) Validation of tissue microarray technology in breast carcinoma. Lab Invest 80(12):1943-1949
28. Chakravarthy A, Kim CR (2002) Post-mastectomy radiation in male breast cancer. Radiother Oncol 65(2):99-103
29. Macdonald G, Paltiel C, Olivotto IA et al (2005) A comparative analysis of radiotherapy use and patient outcome in males and females with breast cancer. Ann Oncol 16(9):1442-1448